• 2'3'-cGAMP (sodium salt): Precision Tool for STING Pathway R

  2026-04-30

  2'3'-cGAMP (sodium salt) is redefining the landscape for STING-mediated innate immune response studies, offering unmatched affinity and water solubility for robust, reproducible experimental workflows. Learn how to leverage this gold-standard reagent for advanced immunotherapy research and troubleshooting complex cGAS-STING signaling assays.

• Cy5-UTP (Cyanine 5-UTP): High-Fidelity Fluorescent RNA Label

  2026-04-30

  Cy5-UTP (Cyanine 5-uridine triphosphate) enables robust, direct fluorescent RNA labeling during in vitro transcription. This substrate yields high-sensitivity, orange-fluorescent RNA probes for applications including FISH and dual-color expression arrays. APExBIO’s B8333 product offers proven stability and spectral specificity, facilitating reproducible, high-impact molecular biology workflows.

• Photothermal Therapy and CD47 Blockade: Synergy in OSCC Trea

  2026-04-29

  This study demonstrates that combining photothermal therapy (PTT) with CD47 blockade leads to a robust anti-tumor response in oral squamous cell carcinoma (OSCC). The innovation lies in PTT's induction of immunogenic cell death and extracellular matrix remodeling, which together enhance macrophage-mediated tumor clearance.

• Selective Vancomycin Agar Enables Recovery of Bovine Moraxel

  2026-04-29

  This study by Leger et al. introduces a vancomycin-based selective medium that improves isolation rates of Moraxella species from bovine specimens, addressing diagnostic and epidemiological gaps in infectious bovine keratoconjunctivitis (IBK) research. The approach refines bacterial recovery from complex sample matrices, with implications for diagnostic workflows and further characterization of emerging Moraxella strains.

• AZD2461: A Next-Generation PARP Inhibitor for Precision DNA

  2026-04-28

  Explore how AZD2461, a novel PARP inhibitor, empowers researchers to dissect DNA repair pathways and overcome drug resistance in breast cancer research. This article delivers a deep dive into assay design, mechanistic insights, and practical guidance distinct from existing overviews.

• Gamithromycin in Translational Respiratory Disease Research

  2026-04-28

  This thought-leadership article provides a mechanistic deep-dive and strategic guidance for translational researchers exploring Gamithromycin (ML-1709460) in the context of veterinary respiratory disease. By integrating molecular pharmacology, advanced PK/PD modeling, and new evidence from foal studies, we outline how APExBIO’s Gamithromycin (BA1074) enables more predictive, impactful research. The discussion bridges bench-to-bedside translation, benchmarked against the competitive landscape and current literature, and concludes with a forward-looking synthesis for the field.

• HOXC8 Suppresses Pyroptosis in NSCLC via Caspase-1 Regulatio

  2026-04-27

  This study unveils a new tumorigenic mechanism in non-small cell lung carcinoma (NSCLC), where HOXC8 suppresses pyroptotic cell death by downregulating caspase-1 expression. These findings link HOXC8-mediated transcriptional control to pyroptosis regulation, revealing novel targets for cancer research and inflammasome activation studies.

• Cy3 Goat Anti-Human IgG (H+L) Antibody: Workflow-Driven Adva

  2026-04-27

  The Cy3 Goat Anti-Human IgG (H+L) Antibody from APExBIO transforms immunofluorescence, immunohistochemistry, flow cytometry, and ELISA with powerful, reproducible signal amplification and flexibility. Explore best practices, troubleshooting, and protocol innovations that enable sensitive human IgG detection across research domains.

• Structural Insights into Gepotidacin vs. Fluoroquinolone Act

  2026-04-26

  This study elucidates the unique mechanism of gepotidacin, a novel bacterial topoisomerase inhibitor, in targeting Staphylococcus aureus DNA gyrase. By contrasting its single-stranded DNA cleavage profile with double-stranded breaks induced by fluoroquinolone antibiotics, the research advances our understanding of resistance mechanisms and informs antibiotic toxicity research.

• Latrunculin B in Translational Science: Mechanism, Strategy,

  2026-04-25

  Explore how Latrunculin B, a cell-permeable actin polymerization inhibitor from APExBIO, enables precision disruption of the actin cytoskeleton in translational research. This article synthesizes mechanistic insights, compares competitive landscape data, and delivers actionable guidance for maximizing impact in cytoskeletal and disease-modeling studies, while critically examining cross-domain relevance and experimental limitations.

• Homoharringtonine Rapidly Clears SARS-CoV-2: Molecular Evide

  2026-04-24

  This study demonstrates that homoharringtonine, a cytotoxic alkaloid, achieves rapid and robust clearance of SARS-CoV-2 in both animal models and human patients by targeting protein synthesis in infected cells. These findings highlight its potential as a first-line intervention for future coronavirus outbreaks, while also clarifying protocol parameters and limitations for translational research.

• Palonosetron Hydrochloride: Advances in Preventing Chemother

  2026-04-24

  Ruhlmann and Herrstedt’s review critically examines palonosetron hydrochloride, a next-generation 5-HT3 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV). Their synthesis highlights palonosetron’s unique pharmacological features, clinical efficacy, and comparative advantages over first-generation agents—offering researchers insight into translational strategies for antiemetic regimens.

• Tankyrase Inhibition Suppresses HCC via Hippo Pathway Modula

  2026-04-23

  Jia et al. (2017) demonstrate that selective tankyrase 1/2 inhibitors, including G007-LK, suppress hepatocellular carcinoma (HCC) cell proliferation through modulation of the Hippo-YAP signaling cascade. The study reveals mechanistic links between tankyrase activity, YAP regulation, and potential therapeutic strategies for HCC.

• Glabridin-Gold(I) Complex Enhances Antitumor Immunity via Tr

  2026-04-23

  A recent study introduces a glabridin-gold(I) complex (6d) that targets TrxR and MAPK pathways, driving immunogenicity and mitigating immunosuppression in liver cancer models. This dual-action strategy advances the mechanistic understanding of metal-based immunomodulators and highlights implications for combinatorial cancer immunotherapy.

• N6-Methyl-dATP: Dissecting Epigenetic Fidelity and Mechanism

  2026-04-22

  Explore the unique mechanistic insights N6-Methyl-dATP brings to epigenetic nucleotide research and DNA replication fidelity studies. This article delivers an in-depth analysis of methylation effects in acute myeloid leukemia (AML), surpassing standard assay discussions with practical, evidence-based parameters.

11244 records 1/750 page Next 12345 下5页 Last page